1. Stocks
    2. /
  2. Imugene Limited (ASX: IMU)
    3. /

Imugene Limited (ASX: IMU) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Imugene Limited Chart and Price Data

Fundamentals Data provided by Morningstar.

Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

    • Imugene Limited (ASX: IMU)
    Latest News

    A group of happy office workers throw papers in the air and cheer.
    Share Gainers

    Here are the top 10 ASX 200 shares today

    | Brooke Cooper

    Do you own shares in today's top-performing ASX 200 stock?

    Read more »

    Share Gainers

    Here are the top 10 ASX 200 shares today

    | Brooke Cooper

    It was a good day to be invested in ASX 200 tech shares...

    Read more »

    A little boy holds up a barbell with big silver weights at each end.
    Share Market News

    Here are the top 10 ASX 200 shares today

    | Mitchell Lawler

    What a way to finish the year...

    Read more »

    A beautiful ocean vista is shown with a woman whose back is to the camera holding her arms up in triumph as she stands at the top of a rock feeling thrilled that ASX 200 shares are reaching multi-year high prices today
    Share Gainers

    Here are the top 10 ASX 200 shares today

    | Brooke Cooper

    Banks and tech led the market on Tuesday.

    Read more »

    Top ten gold trophy.
    Share Gainers

    Here are the top 10 ASX 200 shares today

    | Sebastian Bowen

    Gold shares were amongst some of the only ASX 200 shares in the green today.

    Read more »

    a young woman raises her hands in joyful celebration as she sits at her computer in a home environment.
    Share Gainers

    Why Imugene, Rio Tinto, Santos, and Warrego shares are pushing higher

    | James Mickleboro

    These ASX shares are starting the week strongly...

    Read more »

    A group of science or medical professionals cheering good news in the lab.
    Share Gainers

    Here are the top 10 ASX 200 shares today

    | Brooke Cooper

    Guess which healthcare stock led the index on Tuesday.

    Read more »

    A doctor in a white coat sits at her computer with finger on mouth thinking about something in her office with medical equipment in the background.
    Healthcare Shares

    Why has the Imugene share price tumbled 12% in under a week?

    | Monica O'Shea

    What's going on at Imugene?

    Read more »

    Top ten gold trophy.
    Share Market News

    Here are the top 10 ASX 200 shares today

    | Brooke Cooper

    These ASX 200 shares outperformed all others on Tuesday.

    Read more »

    A beautiful ocean vista is shown with a woman whose back is to the camera holding her arms up in triumph as she stands at the top of a rock feeling thrilled that ASX 200 shares are reaching multi-year high prices today
    Share Market News

    Here are the top 10 ASX 200 shares today

    | Brooke Cooper

    These 10 ASX 200 shares ended the week on a high.

    Read more »

    Top 10 blank list on chalkboard
    Share Market News

    Here are the top 10 ASX 200 shares today

    | Brooke Cooper

    These ASX 200 shares outperformed the index on Wednesday.

    Read more »

    Top ten gold trophy.
    Share Market News

    Here are the top 10 ASX 200 shares today

    | Brooke Cooper

    One ASX 200 share posted an 11% gain on Tuesday.

    Read more »

    Frequently Asked Questions

    Imugene does not pay dividends at this stage. 

    Imugene Ltd (ASX: IMU) listed on the ASX on 24 November 1993.

    IMU ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About Imugene Limited

    Imugene Ltd (ASX: IMU) is a biotechnology company working in cancer immunotherapy.

    The company specialises in clinical-stage immuno-oncology therapies. Its product pipeline includes Oncolytic Virus and B-Cell Immunotherapies aimed at treating a variety of cancers in combination with standard-care drugs and immunotherapies.

    The company's lead product is HER-Vaxx, a proprietary cancer vaccine for the treatment of gastric and breast cancer, where the cancer is HER-2 positive. The vaccine has demonstrated it stimulates a polyclonal antibody response to HER2/neu. 

    Imugene's various immunotherapy products are involved in ongoing clinical trials involving cancer specialists and researchers worldwide.

    Profile

    since

    Note